Company intelligence / Profile preview
Winston Pharmaceuticals
United States
- Ownership
- Private
- Development stage
- Other
01
Overview
Historically, Winston Pharmaceuticals developed small molecule drugs for pain management, with a main asset (civamide nasal solution for cluster headache) reaching Phase 3 trials. The company also advanced products for arthritis, neuropathic pain, headache, and other pain-related indications. Many programs are no longer active, and no recent clinical results or active trials are reported. Status is likely discontinued.
- Therapeutic areas
- DermatologyImmunologyGastroenterologyNeurologyOncologyRheumatology
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Beyond the preview
Go deeper on Winston Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Winston Pharmaceuticals.